- Purifloh is continuing to face troubles collecting reliable data during its tuberculosis trial
- The company highlights the issues stem from trial conditions rather than its Free Radical Generator air purification device
- Shares in the company are trading at $4.91 apiece after a 13.86 per cent drop today
ASX-listed medical company Purifloh has seen its share price suffer today after informing the market of ongoing troubles with its tuberculosis trial.
The company advised it has been unsuccessful in generating reliable baseline data due to issues isolating tuberculosis-causing bacteria from air samples on site.
As a consequence, Purifloh’s share price is down 13.86 per cent, currently sitting at $4.91 apiece, as of 1:34 pm AEST.
Trials testing its Free Radical Generator (FRG) air purification system to eradicate airborne mycobacterium tuberculosis will continue in hospitals despite persistent difficulties.
Difficulties and delays in conducting the trial have been consistent, as outlined across a number of updates by Purifloh this year.
Rapid contamination of the culture by pathogenic molds has continually posed an issue during the trials.
However, according to Purifloh, the troubles in the trials are not due to the function of the FRG device. The company maintains that problems isolating mycobacterium tuberculosis are the cause the issues.